The recent European approval of lutetium (177Lu) oxodotreotide increases treatment options for gastroenteropancreatic neuroendocrine tumors | Zendy

AI Assistant Blog Pricing

Open Access

The recent European approval of lutetium (¹⁷⁷Lu) oxodotreotide increases treatment options for gastroenteropancreatic neuroendocrine tumors

Author(s) -

Martyn Caplin

Publication year - 2018

Publication title -

international journal of endocrine oncology

Language(s) - English

Resource type - Journals

eISSN - 2045-0877

pISSN - 2045-0869

DOI - 10.2217/ije-2018-0002

Subject(s) - neuroendocrine tumors , radionuclide therapy , medicine , lutetium , european union , somatostatin receptor , oncology , somatostatin , cancer research , chemistry , business , organic chemistry , economic policy , yttrium , oxide

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.